Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS‐001 clinical trial

OBJECTIVES: We aimed to evaluate the activity of selinexor, an oral selective inhibitor of nuclear export, in patients with recurrent or metastatic salivary gland tumors (SGT). METHODS: GEMS‐001 is an open‐label Phase 2 study for patients with recurrent or metastatic SGT with two parts. In Part 1 of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernando‐Calvo, Alberto, Malone, Eoghan, Day, Daphne, Prawira, Amy, Weinreb, Ilan, Yang, S. Y. Cindy, Wong, Horace, Rodriguez, Angela, Jennings, Sarah, Eliason, Anneli, Wang, Lisa, Spreafico, Anna, Siu, Lillian L., Hansen, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652322/
https://www.ncbi.nlm.nih.gov/pubmed/37818869
http://dx.doi.org/10.1002/cam4.6589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652322/
https://www.ncbi.nlm.nih.gov/pubmed/37818869
http://dx.doi.org/10.1002/cam4.6589

Ejemplares similares